A. Desiree LaBeaud
Research Subjects
A. Desiree LaBeaud has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Allison Glinka
Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH
1 shared publication- Charles Harding King
Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio
1 shared publication Christopher Kippes
Cuyahoga County Board of Health, Parma, OH
1 shared publication
Latest Publications
- 1 November 2010
- Published by Taylor & Francis in Future Virology
- Vol. 5 (6) , 675-678
Towards a Safe, Effective Vaccine for Rift Valley Fever Virus
Evaluation of: Bhardwaj N, Heise MT, Ross TM: Vaccination with DNA plasmids expressing Gn coupled to C3d or a-virus replicons expressing Gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis. 4(6), E725 (2010). Rift Valley fever virus (RVFV) is an important animal and human threat and leads to long-standing morbidity and mortality in susceptible hosts. Since no therapies currently exist to treat Rift Valley fever, it remains a public and animal health priority to develop safe, effective RVFV vaccines (whether for animals, humans, or both) that provide long-term protective immunity. In the evaluated article, Bhardwaj and colleagues describe the creation and testing of two successful vaccine strategies against RVFV, a DNA plasmid vaccine expressing Gn coupled to C3d, and an alpha-virus replicon vaccine expressing Gn protein. Both vaccines elicited strong neutralizing antibody responses, prevented morbidity and mortality in RVFV-challenged mice, and enabled protection of naive mice via passi...
- 1 November 2010
- Published by Taylor & Francis in Future Virology
- Vol. 5 (6) , 675-678
Towards a Safe, Effective Vaccine for Rift Valley Fever Virus
Evaluation of: Bhardwaj N, Heise MT, Ross TM: Vaccination with DNA plasmids expressing Gn coupled to C3d or a-virus replicons expressing Gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis. 4(6), E725 (2010). Rift Valley fever virus (RVFV) is an important animal and human threat and leads to long-standing morbidity and mortality in susceptible hosts. Since no therapies currently exist to treat Rift Valley fever, it remains a public and animal health priority to develop safe, effective RVFV vaccines (whether for animals, humans, or both) that provide long-term protective immunity. In the evaluated article, Bhardwaj and colleagues describe the creation and testing of two successful vaccine strategies against RVFV, a DNA plasmid vaccine expressing Gn coupled to C3d, and an alpha-virus replicon vaccine expressing Gn protein. Both vaccines elicited strong neutralizing antibody responses, prevented morbidity and mortality in RVFV-challenged mice, and enabled protection of naive mice via passi...
- 31 October 2009
- Published by Elsevier in The Journal of Pediatrics
- Vol. 155 (4) , 590-592.e1
School-Based Health Promotion for Mosquito-Borne Disease Prevention in Children
- 31 October 2009
- Published by Elsevier in The Journal of Pediatrics
- Vol. 155 (4) , 590-592.e1
School-Based Health Promotion for Mosquito-Borne Disease Prevention in Children